Literature DB >> 468984

Acromegaly and vitamin D metabolism: effect of bromocriptine treatment.

P C Eskildsen, B Lund, O H Sørensen, B Lund, J E Bishop, A W Norman.   

Abstract

Fifteen acromegalic subjects were found to have elevated plasma levels of both 1,25(OH)2-vitamin D, 65 +/- 23 (SD) pg/ml [normal 33 + 15 pg/ml (SD)] and 24,25(OH)2-vitamin D, 6.8 +/- 1.6 (SD) ng/ml [normal 3.4 + 1.2 ng/ml (SD)]. Treatment with bromocriptine for 6 months reduced the plasma 1,25(OH)2-vitamin D3 level to 40 +/- 13 (SD) pg/ml, p less than 0.01 and the 24,25(OH)2-vitamin D level to 5.4 +/- 1.7 (SD) ng/ml, p less than 0.05.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 468984     DOI： 10.1210/jcem-49-3-484

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

2.  Control of plasma 1,25-(OH)2-vitamin D concentrations by calcium and phosphorus in the rat: effects of hypophysectomy.

Authors:  R W Gray
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

3.  Bone mineral homeostasis, bone growth, and mineralisation during years of pubertal growth: a unifying concept.

Authors:  S Krabbe; I Transbøl; C Christiansen
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

4.  Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Authors:  Alexandra A Povaliaeva; Viktor P Bogdanov; Artem Yu Zhukov; Ekaterina A Pigarova; Larisa K Dzeranova; Liudmila Ya Rozhinskaya; Galina A Mel'nichenko; Natalia G Mokrysheva
Journal:  Endocrine       Date:  2022-02-09       Impact factor: 3.633

5.  Parathyroid hormone and calcium metabolism in generalized scleroderma. Increased PTH level and secondary hyperparathyroidism in patients with aberrant calcifications. Prophylactic treatment of calcinosis.

Authors:  J Serup; H K Hagdrup
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

6.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

Review 7.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 8.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

9.  Serum vitamin D metabolites do not change in response to intravenous injection of thyrotropin releasing hormone (TRH) and growth hormone releasing factor (GHRF 1-44) in children.

Authors:  R Rosskamp; S Issa; W Burmeister
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

10.  Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration.

Authors:  R Bouillon; F A Van Assche; H Van Baelen; W Heyns; P De Moor
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.